ReviewFrontiers in pharmacology2021
The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Oncogenic EGFR Signaling as a Central Regulator of Chemoresistance in Ovarian Cancer: A Mechanistic Review.International journal of molecular sciences · 2026Review
- Polysaccharide-stabilized biogenic CuO/SeORSC advances · 2026Article
- EGFR-targeted tyrosine kinase inhibitors: advancements in cancer therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Next-generation nanomedicine for cancer therapy: advances, challenges, and future perspectives.Frontiers in chemistry · 2026Review
- Evaluation of silver nitroprusside nanoparticles: selective toxicity against MCF-7 cells and in vivo antitumor activity.Discover nano · 2025Article
- Multi-epitope ligand-conjugated nanoparticles for tumor neoantigen targeting: advancing molecular precision in cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- Extensive Review of Nanomedicine Strategies Targeting the Tumor Microenvironment in PDAC.International journal of nanomedicine · 2025Review
- Synthesis, Characterization, and In-Vitro Evaluation of Silibinin-loaded PEGylated Niosomal Nanoparticles: Potential Anti-Cancer Effects on SW480 Colon Cancer Cells.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Evaluation of Advanced Nanomaterials for Cancer Diagnosis and Treatment.Pharmaceutics · 2024Review
- Nanomedicines: Emerging Platforms in Smart Chemotherapy Treatment-A Recent Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies.International journal of nanomedicine · 2024Review
- Selenium Nanoparticles: Green Synthesis and Biomedical Application.Molecules (Basel, Switzerland) · 2023Review
- Delivery of gene editing therapeutics.Nanomedicine : nanotechnology, biology, and medicine · 2023Review
- Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer.Journal of functional biomaterials · 2023Review
- New insights into nanosystems for non-small-cell lung cancer: diagnosis and treatment.RSC advances · 2023Review
- An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Polydopamine-functionalized selenium nanoparticles as an efficient photoresponsive antibacterial platform.RSC advances · 2023Article
- Potential of Nano-Antioxidants and Nanomedicine for Recovery from Neurological Disorders Linked to Long COVID Syndrome.Antioxidants (Basel, Switzerland) · 2023Review
- Reprogramming the tumor microenvironment with biotechnology.Biomaterials research · 2023Review
- Effect of Size and Concentration of Copper Nanoparticles on the Antimicrobial Activity inNanomaterials (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor (EGFR) is an anticancer drug target for a number of cancers, such as non-small cell lung cancer. However, unsatisfying treatment effects, terrible side-effects, and development of drug resistance are current insurmountable challenges of EGFR targeting treatments for cancers. With the advancement of nanotechnology, an increasing number of inorganic nanomaterials are applied in EGFR-mediated therapy to improve those limitations and further potentiate the efficacy of molecular targeted cancer therapy. Given their facile preparation, easy modification, and biosecurity, inorganic nanoparticles (iNPs) have been extensively explored in cancer treatments to date. This review presents an overview of the application of some typical metal nanoparticles and nonmetallic nanoparticles in EGFR-targeted therapy, then discusses and summarizes the relevant advantages. Moreover, we also highlight future perspectives regarding their remaining issues. We hope these discussions inspire future research on EGFR-targeted iNPs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.